Alma Habib, MD, The Ohio State University Comprehensive Cancer Center, talks about the fact that disparities are able to be recognized in leukemia/lymphoma care, but the questions of how to address these disparities remain.
Addressing disparities in leukemia/lymphoma care is a next step since multiple disparities have already been identified, discusses Alma Habib, MD, hematology medical oncology fellow at The Ohio State University.
Transcript
How are disparities in leukemia/lymphoma treatment being addressed in the current treatment landscape?
I think over the past few years, we've really done a good job of identifying disparities in our research. We've uncovered disparities in cancer care related to aging, gender, socioeconomic status, insurance status, and even through DNA sequencing. We've also uncovered that every individual has a different type of cancer, especially patients from minority racial groups. Their cancer may look different. Black patient cancers may look different from White patient cancers. I think we've really done a good job about uncovering these disparities and differences in cancer. For example, in acute myeloid leukemia, we know that Black patients have more mutations that are considered less favorable than White patients. This really impacts the way we treat their disease and their survival rates.
But I think the most important question to ask now that we've uncovered disparities is, what do we do about them? And what can we do as a health care team to improve outcomes for patients? The answers to these questions are largely going to be based on the patient. Every individual patient has different barriers to their treatment, to their access. I think a lot of our efforts now need to be focusing on that. How can we overcome the barriers that patients face in order for them to get the best care possible? And how can we improve access to clinical trials and these new treatments that we've developed?
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More